Gilead Sciences Inc. (NASDAQ:GILD) Saws One More Success About Sovaldi Approval- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), Kite Pharma, Inc. (NASDAQ:KITE)

March 27, 2015 6:25 PM

13 0

Gilead Sciences Inc. (NASDAQ:GILD) [Detail Analytic Report] proclaimed that Ministry of Health, Labour and Welfare of Japanese has sanctioned Sovaldi, a once-daily nucleotide analog polymerase inhibitor, for the suppression of viremia in patients with genotype II chronic hepatitis C virus infection with or without compensated cirrhosis. Sovaldi is showed for use in grouping with ribavirin for twelve weeks. Sovaldi in grouping with RBV is the first all-oral, interferon-free treatment regimen for genotype II HCV infection. Sovaldi is also the first product to be sold by the firm in Japan. Masao Omata, MD, Yamanashi Prefectural Hospital Organization stated that this authorization represents a significant move ahead in the management of hepatitis C in Japan, allowing genotype II infected patients the prospect of a cure in twelve weeks with an all-oral regimen that reduces the need for interferon. Norbert Bischofberger, Executive VP of R&D and Chief Scientific Officer at Gilead stated that there is a need in Japan for new HCV treatment options that are further effective and better tolerated and they have been happy to partner with the medical community here in Japan to show the efficiency and safety of Sovaldi. They look onward to making Sovaldi accessible in Japan as soon as possible, while at the same time continuing to work with the agency on its review of their second application for an all-oral sofosbuvir-based regimen for the treatment of genotype I HCV infection.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) [Detail Analytic Report] publicized that Daniel Soland has moved into BOD of the firm. Mr. Soland is an experienced pharmaceutical executive with above 30 years of involvement in the biopharmaceutical industry. Leslie L. Iversen, Ph.D., Chairman of Board of ...

Read more

To category page